GE seeks worthy device, Dx startups for $250M investment fund; Boston Sci, Philips sign marketing deal;

 @FierceMedDev: Folks, the clock is ticking. Get your nominations in for the 15 fiercest device developers. Survey | Follow @FierceMedDev

> General Electric ($GE) is still looking for startups focused on devices, medical imaging, in vitro diagnostics, life sciences instruments and other spaces in which to invest from its $250 million Healthymagination Fund, says the fund's managing director, Noah Lewis. Story

> Boston Scientific ($BSX) has sealed a deal with Royal Philips Electronics, enabling the company to sell Boston Scientific imaging equipment globally that's compatible with its own imaging systems. Story

> Chinese device company Dehaier Medical ($DHRM) has launched a U.S. subsidiary to help fuel international expansion for the company's products including sleep diagnostic devices and oxygen inhalators. Release

> The FDA has signed off on expanded use for the FilmArray Respiratory Panel, allowing the molecular diagnostic test to also be used for pertussis and two forms of pneumonia. It is the first FDA-cleared test of its kind that can test for the three bacteria. Release

> Cerebain Biotech in Irvine, CA, entered a partnership with medical device development company Sonos Models to assess its options for a medical device product. Release

> In the weeks before Asahi Kasei's $2.3 billion agreement to buy Zoll Medical closed in April, the SEC cleared Zoll of having any suspicious ties to Iran, Syria, Sudan or other "state sponsors of terrorism." The government had launched the investigation based on Zoll's sales to Iran, MassDevice reports. Story

Biotech News

 @FierceBiotech: MIT: Staggering cancer drugs can make them more effective. More | Follow @FierceBiotech

 @RyanMFierce: It's only a matter of time before fat taxes are everywhere. Obesity costs too much, and taxes on smokes paved the way. Report | Follow @RyanMFierce

 @JohnCFierce: Stealth no more: Ra Pharma in Cambridge nails $8.6M venture tranche, targets hereditary angioedema for the lead. Article | Follow @JohnCFierce

> Elevation boasts 'gold standard' IIb data for COPD therapy. Item

> Achillion burnishes buyout prospects, snags fast track for hep C drug. News

> Cancer drug experts brace for ASCO abstract dump tonight. More

Pharma News

 @FiercePharma: Patients 'waiting up to nine years' for NICE to approve drugs, a U.K. study finds--TelegraphStory | Follow @FiercePharma

> Top 10 Best-selling Cancer Drugs in 2011. Special report

> New discount persuades NICE to bless J&J's Zytiga. News

> U.K. report says NICE drags its feet on drug approvals. Article

> ASCO data to shine new light on Pfizer, Roche, J&J drugs. Story

Drug Delivery News

 @DamianFierce: Using self-assembling DNA tubes, Harvard researchers plan to effectively deliver drugs to cells. News | Follow @DamianFierce

> UNC researchers craft siRNA platform that can switch its solubility. Report

> MIT: Staggering cancer drugs can make them more effective. Story

> Japanese firm buys Altea's assets, plans to launch transdermal tech. Article

> D. Medical signs worldwide marketing deal for insulin-delivery tech. Item

Biomarkers News

> Genes tag schizophrenia risk. More

> Proteins in a drop of fluid mark osteoarthritis risk. Report

> Early pancreatic biomarker could spot killer disease. Article

> Gene IDs fast-onset Parkinson's disease. Story

And Finally... Thieves at the Florida Hospital Center for Diagnostic Pathology stole $500,000 worth of medical machines, that, unbeknownst to them, were loaded with flesh-eating bacteria. Blog

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.